Why Sell? To get a return on investment, private company shareholders may want to sell shares now instead of waiting until a 'possible' later time when the company will be acquired or go public in an initial public offering (IPO). Given that the length [...]
About B2WorldThis author has not yet filled in any details.
So far B2World has created 18 blog entries.
Based upon my experience as an international business lawyer and business developer, many companies do not place the same emphasis on legal risk management when it comes to websites as compared with business contracts. In light of this, I thought it would prove useful [...]
What is a Residuals Clause? A residuals clause is a legal exception to confidentiality under non-disclosure agreements or other agreements containing confidentiality provisions. For instance, let's assume you (the "discloser") disclose highly sensitive information to a receiving party (the "recipient") under a non-disclosure agreement [...]
What is a Non-Disclosure Agreement (NDA)? An NDA, generally speaking, is an agreement between two parties regulating the exchange of confidential information for a specific purpose (often evaluating a future business deal). Beyond evaluation purposes, NDAs can be used to safeguard highly sensitive information [...]
Business development is by no means easy, especially when companies are developing innovative products and services. Learning from the mistakes of other companies can save time, money, and a lot of frustration. Over my 15 years of practice representing emerging technology companies, I [...]
Many Swedish companies aim to sell products or services in the United States. The timeline for ‘when’ to do so can be based on factors such as demand, funding, staffing, existing channel contacts, the ability to localize the offerings, demographics, intellectual property (“IP”) [...]
"OssDsign AB is a Swedish med-tech company emerging from academic research by Clinical Researchers at Karolinska Hospital and Biomaterial Researchers at Uppsala University. OssDsign has developed a unique technology for 3-D printed, patient specific, bioactive implants addressing clinical complications related to traditional implant technologies. [...]